Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RNAC
CARTESIAN THERAPEUTICS, INC.
NASDAQ
$9.60
▼ DOWN 3.71% (-0.37)

KEY STATISTICS

Market Cap$282.06 M
52w High$11.00
52w Low$5.60
Dividend Yield—
Frequency—
P/E-2.55
Volume65.55K
Shares Out.29.38M

COMPANY

LEADERSHIP

Carsten Brunn
CHIEF EXECUTIVE
Carsten Brunn

COMPENSATION 2026

Salary$674,000
Stock Awards$973,475
Incentive Plan Pay$363,960
All Other Comp.$4,113
Total$4,329,868

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 22, 2016
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
75

PRICE TARGET

Target High$25.00
Target Low$16.00
Target Median$20.50
Target Consensus$20.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$150.00K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2024-04-05Reverse1:30

PRICE

$9.60 ▼ DOWN 3.71% (−$0.37)
OVERLAYS
$9.50$9.75$10.00$10.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.60

About Cartesian Therapeutics, Inc.

https://cartesiantherapeutics.com ↗

Selecta Biosciences is a clinical-stage biopharma developing nanoparticle immunomodulatory drugs and gene therapies for autoimmune, genetic, and inflammatory diseases, with several programs in Phase I and III trials.

INDUSTRY

Biotechnology

A PRODUCT CARTESIAN THERAPEUTICS, INC. IS KNOWN FOR

Descartes-08
Descartes-08

Descartes-08 is a Phase 3 mRNA CAR-T therapy for autoimmune diseases like myasthenia gravis, administered without preconditioning chemotherapy, and is Cartesian's leading product candidate under clinical development.

COMPETITORS

COMPETITOR
ALLO COMPARE
CABA COMPARE
CRSP COMPARE
FATE COMPARE
KYTX COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q4-2025Q1-2026
Operating Segment$1.1M $298K ▼$1.4M ▲$78K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
47
LISTED HERE
8
RANKED BY POSITION SIZE
VTI
0.00% · 376.3K
XSU.TO
0.00% · 334.2K
JSML
0.53% · 196.3K
R2SC.L
0.01% · 38.9K
QQQS
0.63% · 14.8K
XRSG.L
0.00% · 12.5K
RSSL
0.00% · 6.2K
URTY
0.00% · 534

INSTITUTIONAL OWNERSHIP

SHARES OWNED
28.37%
HOLDERS
105
TOP 12 OF 105 · RANKED BY POSITION SIZE
Squarepoint Ops LLC
2.2M sh · $13.77M
Fmr LLC
2.2M sh · $22.03M
Blackrock, Inc.
649.3K sh · $6.64M
Siren, L.L.C.
563.3K sh · $5.76M
Vanguard Group Inc
541.2K sh · $3.9M
Blackrock Inc.
407.6K sh · $11.01M
Bioimpact Capital LLC
380.0K sh · $3.88M
683 Capital Management, LLC
330.0K sh · $2.03M
Millennium Management LLC
284.3K sh · $1.75M
Erste Asset Management Gmbh
271.7K sh · $1.96M
Geode Capital Management, LLC
263.7K sh · $1.62M
Marshall Wace, Llp
251.1K sh · $1.54M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
10 PERCENT OWNER
Kalayoglu Murat
Sale · 22.7K shares
2026-04-02
★
10 PERCENT OWNER
Hoge Elizabeth
Purchase · 758.0K shares
2026-04-02
★
10 PERCENT OWNER
Hoge Elizabeth
Sale · 22.7K shares
2026-04-02
★
10 PERCENT OWNER
Kalayoglu Murat
Purchase · 758.0K shares
2026-04-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM BTIG BUY Needham BUY HC Wainwright & Co. BUY Cantor Fitzgerald OVERWEIGHT

SECTORS PEERS

PEERPRICE
AVTX$19.59COMPARE
FENC$12.27COMPARE
OBIO$5.18COMPARE
IVA$4.71COMPARE
EPRX$6.67COMPARE
MDWD$12.66COMPARE
AARD$5.79COMPARE
NTHI$4.69COMPARE